Immatics (IMTX) Other Accumulated Expenses (2019 - 2025)
Immatics (IMTX) reported Other Accumulated Expenses of $6.5 million for Q4 2025, down 10.25% on a YoY basis from $7.3 million in Q4 2024, and up 21.45% sequentially from $5.4 million in Q3 2025.
Immatics (IMTX) Other Accumulated Expenses (2019 - 2025) Analysis & Trends
Immatics (IMTX) has 7 years of Other Accumulated Expenses data on file, last reported at $6.5 million in Q4 2025.
- For the quarter ending Q4 2025, Other Accumulated Expenses fell 10.25% year-over-year to $6.5 million; the trailing twelve-month figure through Dec 2025 stood at $6.5 million (down 10.25% YoY), and the FY2025 full-year result was $6.3 million, down 13.99% from the prior year.
- Other Accumulated Expenses improved to $6.5 million in Q4 2025, from $5.4 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $16.6 million in Q3 2024 to a low of $1.7 million in Q1 2021.
- A 5-year average of $6.7 million and a median of $7.1 million in 2024 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses tumbled 85.38% in 2021 and jumped 377.4% in 2023, its largest moves.
- Tracing IMTX's Other Accumulated Expenses over 5 years: stood at $2.9 million in 2021, then surged by 227.31% to $9.6 million in 2022, then advanced by 5.26% to $10.1 million in 2023, then dropped by 27.7% to $7.3 million in 2024, then slipped by 10.25% to $6.5 million in 2025.
- Business Quant data shows IMTX's Other Accumulated Expenses at $6.5 million in Q4 2025, $5.4 million in Q3 2025, and $7.7 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Immatics | 1.11 Bn | 568.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.53 Mn |
| Sep 30, 2025 | 5.37 Mn |
| Jun 30, 2025 | 7.65 Mn |
| Mar 31, 2025 | 6.99 Mn |
| Dec 31, 2024 | 7.27 Mn |
| Sep 30, 2024 | 16.64 Mn |
| Jun 30, 2024 | 10.79 Mn |
| Mar 31, 2024 | 10.42 Mn |
| Dec 31, 2023 | 10.06 Mn |
| Sep 30, 2023 | 8.29 Mn |
| Jun 30, 2023 | 8.63 Mn |
| Mar 31, 2023 | 8.57 Mn |
| Dec 31, 2022 | 9.56 Mn |
| Sep 30, 2022 | 4.40 Mn |
| Jun 30, 2022 | 3.11 Mn |
| Mar 31, 2022 | 1.80 Mn |
| Dec 31, 2021 | 2.92 Mn |
| Sep 30, 2021 | 1.73 Mn |
| Jun 30, 2021 | 1.74 Mn |
| Mar 31, 2021 | 1.71 Mn |